.png){kind=icon}
.png){kind=icon}
Return
Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis
.png){kind=icon}
OA
AI
P
M
J
DOI：10.1016/j.jacbts.2026.101595.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Cardio- and renoprotective effects expand SGLT2 inhibitor use beyond diabetes. • This review highlights SGLT2 inhibitors in aortic stenosis and pressure overload. • Disease-modifying potential of SGLT2 inhibitors in aortic stenosis warrants study.
Keywords:
aortic stenosis
dapagliflozin
flozin
heart disease
SGLT2 inhibitors
empagliflozin
AGE
advanced glycation end product
AS
aortic stenosis
AV
aortic valve
AVR
aortic valve replacement
BMP
bone morphogenetic protein
HF
heart failure
LV
left ventricle/ventricular
NF-κB
nuclear factor κB
NHE1
sodium-hydrogen exchanger 1
ROS
reactive oxygen species
SGLT2
sodium-glucose cotransporter 2
SGLT2i
sodium-glucose cotransporter 2 inhibitor(s)
TAC
transverse aortic constriction
TAVR
transcatheter aortic valve replacement
TGF-β
transforming growth factor-β
VIC
valvular interstitial cell
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
J
IF:
0
Papers:
81
Citations:
0
Organization
Cited Papers